Peritoneal Dialysis International, Vol. 17, pp /97 $ THE PERITONEAL CAVITY OF RATS
|
|
- Caroline Moore
- 6 years ago
- Views:
Transcription
1 Peritoneal Dialysis International, Vol. 17, pp /97 $ Printed in Canada All rights reserved Copyright 1997 International Soeiety for Peritoneal Dialysis CHRONIC ADMINISTRATION OF IRON DEXTRAN INTO THE PERITONEAL CAVITY OF RATS Sang-Eun Park, Zbylut J. Twardowski, Harold L. Moore, Ramesh Khanna, and Karl D. Nolph Division of Nephrology, Department of Medicine, University of Missouri, Harry S. Truman Veterans Administration Hospital, Dalton Research Center, Columbia, Missouri, U.S.A..Objective: To determine the influence of chronic iron dextran administrations into the peritoneal cavity of rats on function and anatomy of the peritoneal membrane, as well as on erythropoiesis and serum iron..design: Prospective randomized animal study..setting: Animallaboratory..Animals: 36 Sprague-Dawley rats..interventions: The rats were divided into three groups (n = 12). The animals were given standard 1.5% Dianeal (control group) or 1.5% Dianeal containing iron dextran in a concentration of 2 mg/l [Iow-dose group (LDG)] or 10 mg/l [high-dose group (HDG)]..Main outcome measures: On the 8th day, at 3 months, and at 6 months a 2-hour peritoneal equilibration test (PET) and blood tests including hematocrit, serum iron, and total ironbinding capacity (TIBC) were done. After the final PET at 6 months, the peritoneal membrane was evaluated by gross inspection and by light microscopy..results: Hematocrit and serum iron levels increased only in the HDG and LDG. Peritoneal transport of small solutes decreased significantly in the HDG compared to baseline. All cases of the HDG group revealed peritoneal adhesions and fibrosis around the peritoneal catheter as well as massive iron deposits on the peritoneum. Similar but less pronounced changes were found in the LDG..Conclusions: These findings suggest an efficient absorption of iron from the peritoneal cavity of rats, however, dialysate iron dextran concentrations of 2 mg/l or greater are toxic to the peritoneal membrane. Therefore, future studies should be performed to determine the minimal effective and nontoxic iron dextran concentrations for intraperitoneal administration. KEY WORDS: Iron dextran; peritoneal fibrosis; iron toxicity; rats. A nemia is one of the most serious complications of end-stage renal disease that often cannot be corrected by dialysis. The use of recombinant human erythropoietin (rhuepo) to treat anemia in end Correspondence to: Z.J. Twardowski, Division of Nephrology, MA 436 Health Sciences Center, University of Missouri, Columbia, Missouri, 65212, U.S.A. Received 3 October 1996; accepted 18 January stage renal disease has been a major advance in the care of patients receiving hemodialysis or peritoneal dialysis (PD) (1). Such erythropoietin replacement therapy is frequently associated with the development of functional iron deficiency due to the massive transfer ofbone marrow iron stores to erythroid progenitor cells, so erythropoietin replacement therapy requires long-term maintenance therapy with iron, with fre quent monitoring for adequacy of iron stores (2-6). Compared to hemodialysis patients, PD patients are less prone to iron deficiency, however, they do require iron supplementation to compensate for losses of blood through the gastrointestinal tract, menstruation, and phlebotomy for laboratory tests. Available iron delivery routes are intravenous injection (7-9), intramuscular injection (10), and oral admin istration of iron (11,12). Intravenous administration is inconvenient for PD patients because of poor intravenous access. In addition, intravenous iron dextran infusion has been occasionally associated with serious reactions including hypotension, respiratory failure, and anaphylaxis (13,14). Intramuscular iron dextran injection has been suggested, but there have been some reports of development of sarcoma at the injection site after chronic intramuscular iron injection (15,16). Oral administration of iron may be limited by patient non-compliance, poor oral absorption, gastrointestinal side effects, and interactions with other oral medications (11). If the intraperitoneal route of iron delivery were available, it would be much more convenient for the PD patients. Our previous acute studies (17,18) with the 6-hour cycle showed that more than 70% of iron dextran injected into the peritoneal cavity ofrats is absorbed from the peritoneal cavity. There was no evidence of macroscopic change of the peritoneum or microscopic iron deposition on the peritoneum in the acute study. The goals of this chronic study were to determine the influence of chronic iron dextran administrations into the peritoneal cavity of rats on function and anatomy of the peritoneal membrane, serum iron, and hematocrit.
2 MATERIALS AND METHODS ANIMAL TREATMENT Thirty-six male Sprague-Dawley rats weighing g were divided into three groups (n = 12). Group 1 (control group) was given standard 1.5% Dianeal PD-2 (Baxter Health Care Inc., IL, U.S.A.). Group 2 (low-dose group) was given 1.5% Dianeal with 2 mg/l concentration of iron dextran. Group 3 (high-dose group) was given 1.5% Dianeal with 10 mg/l concentration of iron dextran. For the experimental, low-, and high-dose groups the iron in the form of iron dextran injection (InFeD, Schein Pharmaceutical, Florham Park, NJ, U.S.A.) was added to the dialysis solution. Iron dextran is available in 2-mL ampules containing 50 mg/ml elemental iron. The solution contains approximately 20% dextran with molecular weight 160 to 180 KD. For the low-dose group, 50 μg of elemental iron was added to 25 ml of dialysis solution (2 mg/l). For the high-dose group, 250 μg of elemental iron was added to 25 ml of dialysis solution (10 mg/l). The iron was delivered by infusion of the dialysis solution through an intraperitoneal catheter. CATHETER (19) IMPLANTATION The animals were placed supine on a 37 C heating pad in a large jar and anesthetized with methoxy flurane (Metofane, Mallinckrodt Veterinary, Mundelein, IL, U.S.A.). The anesthesia was main tained with a nose cone. The abdomen was shaved and disinfected with Amukin (Amuchina, Genova, Italy). The area was then covered with Tegaderm (3M Corporation, St. Paul, MN, U.S.A). An incision was made in the skin along the midline starting at the xiphoid process and extending caudally approximately 3 cm. A blunt dissection was then done on the midline through the abdominal wall approximately 0.75 to 1.5 cm below the xiphoid process. Once the cavity was penetrated, the tip of the catheter was advanced into the cavity and secured with a single stitch through the cuff material and the superficial muscle layer. The procedure was performed carefully to avoid bleeding and trauma to the peritoneum. The hole into the peritoneum was large enough to allow the catheter to pass through but small enough that the catheter fitted snugly. With the use of the 3 mm trocar, the other end of the catheter was tunneled under the skin to the point near the animal's scapula that had been shaved and disinfected. The trocar was then forced through the skin and the catheter pulled through the tunnel. When the second cuffwas next to the exit hole, the catheter was trimmed leaving approximately 1.5 to 2.0 cm exposed. The catheter was capped. The animals were allowed to wake up, placed again in their cages, and allowed free access to food and water. The animals were given buprenorphine subcutaneously for analgesia with the dose adjusted as needed. This analgesic therapy was continued for 72 hours post surgery. INTRAPERITONEAL DIALYSIS SOLUTION ADMINISTRATIONS Twenty-five ml of either the control or one of the experimental dialysis solutions was administered into the peritoneal cavity through the catheter each morning, 7 daysa-week, for 6 months. The first administration was done on the day of catheter implantation. The nonabsorbed dialysate was drained each morning before the next administration and cultured for bacterial growth. Every effort was made to avoid system contamination. TREATMENT OF PERITONITIS Diagnosis of peritonitis was based on culture results (more than 10 colonies on a blood agar plate). Upon diagnosis ofperitonitis, the animal was treated intraperitoneally with a loading dose of vancomycin (1 g/l) and gentamicin (1.7 mg/kg), followed with a maintenance dose of 30 mg/l and 8 mg/l, respectively, per exchange for one week. PERITONEAL MEMBRANE FUNCTION AND BLOOD TESTS On the eighth day, at 3 months, and at the last exchange (6 months) the animals were anesthetized, as outlined above, 2 hours after the instillation of the dialysis solution. After a 2-hour dwell, a 5 ml dialy sate sample was collected through the catheter and sent for chemistry and bacteriology analysis. Imme diately thereafter, a 2 ml sample of blood was taken by direct cardiac puncture for hematocrit, serum iron, and total iron-binding capacity (TIBC). In the case of peritonitis, the dialysate and blood samples were deferred until the membrane inflammation had subsided, that is, 2 days after an antibiotic had been discontinued. Peritoneal equilibration tests (PET) were performed by measuring glucose concentration in the fresh dialysis solution (DO) and dialysate after a 2-hour dwell (D). Glucose concentrations in the samples were determined by an autoanalyzer ASTRA-8 (Beckman Instruments, Brea, CA, U.S.A.). LABORATORY TESTS Serum iron, TIBC, and hematocrit were determined on blood samples obtained through cardiac
3 puncture on the eighth day, at 3 months, and at 6 months. Serum Fe and TIBC were determined by a colorimetric procedure using a commercial iron and total ironbindingcapacity kit (Sigma Chemical company, St. Louis, MO, U.S.A.). TISSUE SAMPLING After the final PET at 6 months, the abdomen was opened, the solution completely drained, and the peritoneal membrane was evaluated by gross inspection and by light microscopy after staining with Prussian blue. Tissue samples were taken from the small intestine, mesentery, and 3 regions of the abdomen, both lateral walls, and the diaphragm. The study was terminated before 6 months in animals with poorly-functioning or nonfunctioning catheters, but tissue samples were obtained for pathology at that time. The catheter was considered to be poorlyfunctioning if fluid could be infused into the peritoneal cavity, but could not be drained (one-way obstruction). In nonfunctioning catheters, the fluid could be neither infused nor drained (two-way obstruction). STATISTICAL ANALYSIS The results of this chronic study were analyzed by looking at the quantitative morphological changes in the peritoneum, including adhesions, fibrosis, and iron deposition. Regarding PET and laboratory data, simple t- tests for unpaired comparisons were performed by a Sigmastat program. One way ANOV A and the Student- Newman-Keuls method were also applied. Variables are shown as mean ± SD; p < 0.05 was considered statistically significant. RESULTS Table 1 shows hematocrit, serum iron, and TIBC at baseline, at 3 months, and at 6 months of study. The mean hematocrit was significantly higher than at baseline in the high-dose group at 3 months (47.9 ± 1.5 vs 43.0 ± 2.7; p < 0.05) and at 6 months (48.4 ± 1.8 vs 43.0 ± 2.7; p < 0.05). At 6 months, the mean hematocrits were significantly higher in the high-dose and low-dose groups compared to the control group (48.4 ± 1.8,46.4 ± 0.9, and 44.2 ± 1.4, respectively; p < 0.05). There was also a significant difference in hematocrit between the high-dose group and the low-dose group at 6 months (48.4 ± 1.8 vs 46.4 ± 0.9). Finally, at 6 months, the hematocrit was higher in the low-dose group compared to baseline (46.4 ± 0.9 vs 44.1 ± 2.3; p < 0.05). There were no significant differences in the mean serum iron among the three groups at baseline. Serum iron levels were significantly higher in the high-dose group at 3 and 6 months, compared to baseline and the control group. At 3 months, serum iron in the high-dose group was also significantly higher than in the low-dose group. In the lowdose group, serum iron was significantly higher than in the control group at 3 and 6 months. In the control At baseline, body weights in grams (mean ± SD) were 362 ± 21.7,332.7 ± 36.1, and ± 21.5 in control, low-dose, and high-dose groups, respectively. The differences were not significant. Seven, eight, and three rats had functioning catheters at 3 months in the control, low-dose, and highdose groups, respectively. At 6 months, the number of functioning catheters dropped to five, six, and three in these groups, respectively. The animals with poorly functioning or nonfunctioning catheters were sacrificed and tissue samples taken for pathology. In the control group, five rats were sacrificed by the third month and two more by the sixth month; in the lowdose group, four rats were terminated by the third month and two mo re by the sixth month. In the highdose group, nine rats were sacrificed by the third month. All other animals completed 6 months of study.
4 group compared to baseline, serum iron was significantly lower at 3 months but was not significantly different at 6 months (Table 1). There was no significant difference in TIBC at baseline among the three groups. Although mean TIBC was increased in the low-dose group at 3 months, there was no significant difference among the three groups at 6 months (Table 1). Peritoneal transport properties were assessed by calculating the ratio of dialysate glucose after a 2hour dwell (D) to glucose concentration in dialysis solution (DO). The higher the ratio the lower the transport of small solutes. Baseline 2-hour DIDO ratios of glucose were 0.24, 0.26, 0.23 in the control, low-dose, and high-dose groups respectively. This is consistent with other PD studies in rats. There were no significant differences in glucose DIDO ratios at 2hour dwell among the groups at baseline. Mean DIDO ratios of glucose were significantly increased at 3 months compared to baseline in all groups (p < 0.05). Compared to the other groups, the DIDO ratio of glucose was higher in the high-dose group at 6 months (p < 0.05). At 6 months, DIDO glucose ratios after a 2-hour dwell in the high-dose, low-dose, and the control groups were 0.38 ± 0.10,0.33 ± 0.07, and 0.25 ± 0.12, respectively (Table 2). At 6 months, one case (20%) in the control group and the three cases (50%) in the low-dose group revealed adhesions of the peritoneum, while all cases (n = 3) of the high-dose group revealed adhesions. Fibrosis around the catheter was noted in one case (20% ) in the control group, two cases (33% ) in the lowdose group, and in all cases (100%) in the high-dose group. Compared to the control and low-dose groups, which didn't show any pigmentation of the peritoneum, two cases in the high-dose group showed dark brown pigmentation on the peritoneum of the mesentery and the abdominal wall by gross inspection (Table 3, Figure 1). Pericatheter fibrosis was found in all rats sacrificed before the end of the study and was the reason for catheter failure. At 6 months, Prussian blue staining of the peritoneum did not reveal any iron deposits in the control group. In the low-dose group at 6 months, there were numerous iron particles in the peritoneum of the abdominal wall and mesentery (Figure 2). In the high-dose group at 6 months, there were massive iron deposits in the peritoneum of the mesentery and abdominal wall (Figure 3). Dark spots, visible macroscopically as brown pigmentation on the peritoneal membrane, were produced by massive iron aggregates, as revealed microscopically after Prussian blue staining (Figure 4). Mild iron deposits were found in the high-dose group animals sacrificed at 1.5 months, but no such deposits were seen in the control and low-dose groups at 1.5 and 3 months. The incidence of peritonitis was 0.55Imonth/rat in the control group, 0.56Imonth/rat in the low-dose group and 0.52Imonth/rat in the high-dose group. There was no significant difference of incidence of peritonitis among the groups.
5 DISCUSSION Recombinant human erythropoietin (rhuepo ) has been associated with subjective and objective improvements in quality-of-life in patients with anemia of chronic renal failure (1). However, resistance to rhuepo therapy may occur due to insufficient iron stores. Although many patients treated with rhuepo take oral iron, patients continue to develop iron deficiency (20). Parenteral iron is used as an effective alternative for replacing iron stores to sustain erythropoiesis in hemodialysis patients treated with rhuepo (10). In PD patients, intravenous iron administrations are inconvenient; an intraperitoneal route of iron delivery would be much more convenient. Iron dextran (InFeD) contains ferric iron combined with dextran which has a molecular weight of 160 to 180 KD. It is commercially available and is widely used for dialysis patients, in spite of known anaphylactoid reactions to dextran (13,21). Hematocrit increased in those groups that were administered solutions containing iron dextran. Mean serum iron levels increased markedly at 3 and 6 months in the high-dose group and at 6 months in the low-dose group. While serum iron levels decreased significantly at 3 months in both the low-dose and control groups, this may be due to blood sampling by cardiac puncture. TIBC increased at 3 months in the low-dose group, but there was no significant difference in TIBC among the groups at 6 months. In this chronic study, these results suggest that the improved erythropoiesis observed with both the low and high-dose groups, when compared with the control group, was most likely due to an improvement in availability of iron induced by intraperitoneal iron administration. We investigated the effect of chronic intraperitoneal iron administration on the peritoneum using the peritoneal equilibration test in rats. The D/DO ratio increased significantly from baseline in all the groups at 3 months. Compared to the DIDO ratio of the control group at 6 months, which returned back to baseline level, the D/DO ratio of the high-dose group was still high at 6 months. An increased D/DO ratio of glucose means that the transport of glucose is reduced. This indicates a decrease in the effective peritoneal surface area or permeability. Based on the DIDO ratio, peritoneal function was poor in the highdose group compared to the control group at 6 months. These results indicate that chronic intraperitoneal administration of iron dextran affects the function of peritoneum. Gross inspection of the peritoneum showed striking alterations in both the low and high-dose groups. While only one case in the control group revealed adhesions of the peritoneum and fibrosis around the
6 catheter, all cases in the high-dose group showed adhesions and fibrosis around the catheter. Brown pigmentation, resulting from deposition of iron, was noted in the highdose group only. This means that chronic intraperitoneal administrations of a high dose of iron dextran can cause anatomical changes including adhesion, fibrosis, and iron deposition. Histological findings confirmed massive iron deposits on the peritoneum of the mesentery and on the parietal peritoneum, especially in the high-dose group. Chronic intravenous or intraperitoneal administration of iron dextran can damage some organs including the peritoneum. The main target organs of iron deposition are the liver, bone marrow, the spleen, and other tissues (22). Schwartz et al. studied a guinea pig model ofiron-overload toxicity induced by intraperitoneal iron dextran administration (23). They found marked iron deposition including iron particles and aggregates in the liver, heart, and bone marrow. Mild iron deposition was noted in our study in the high-dose group at 1.5 months and in the lowdose group at 6 months. The total amount of iron dextran administered was 9 mg for 6 months in the low-dose group and 11 mgfor 1.5 months in the highdose group. The total amo unt of iron dextran was 45 mg for 6 months in the high-dose group which revealed marked iron aggregates of iron particles. These facts support the hypothesis that the degree of iron deposition is directly proportional to the amount of iron dextran administered intraperitoneally. In this chronic study, more than half of the animals were terminated early due to poor catheter function. The major cause of poor catheter function was frequent peritonitis leading to peritoneal adhesions. The other possible cause of poor catheter function seemed to be due to the development of peritoneal adhesions related to the high concentration of intraperitoneal iron dextran. In conclusion, this study suggests that iron dextran is efficiently absorbed from the peritoneal cavity; dose-related development of adhesions and peritoneal iron deposits indicate that the concentration of iron in the peritoneal cavity should be lower than 2 mg/l. Future studies are needed to determine the optimal intraperitoneal iron dextran concentration: high enough to deliver a sufficient amount ofiron, yet low enough to avoid peritoneal toxicity. ACKNOWLEDGMENT Supported in part by a grant fromamgen, Inc. (EPO ). REFERENCES 1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 1989; 35: Anastassiades EG, HowarthD, HowarthJ,etal. Monitoring ofiron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 1993; 8: Macdougall IC, Cavill I, Hulme B, et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. Br Med J 1992; 304: Sunder-Plassmann G, Horl WH. Iron metabolism and iron substitution during erythropoietin therapy. Clinical Investigator 1994; 72(Suppl 6):Sll York S. Current perspectives: iron management during therapy with recombinant human erythropoietin. ANNA J 1993; 20: Burns DL, Mascioli EA, Bistrian BR. Parenteral iron dextran therapy: a review. Nutrition 1995; 11: RosenlofK, Kivivuori SM, Gronhagen-Riska C, Teppo AM, Slimes MA. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis. Clin Nephrol 1995; 43: Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: Suh H, Wadhwa NK. Iron dextran treatment in peritoneal dialysis patients on erythropoietin. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin 1992; 8: Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995; 25: Raja R, Bloom E, Johnson R. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications 1993; 9: Michelson E. Anaphylactoid reaction to dextran. N Engl J Med 1968; 278: Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243: MacKinnon AE, Bancewicz J. Sarcoma after injection of intramuscular iron. Br Med J 1973; 2: Grasso P. Sarcoma after intramuscular iron injection. Br Med J 1973; 2: Suzuki K, Twardowski ZJ, Nolph KD, Khanna R, Moore HL. Absorption of iron from the peritoneal cavity ofrats. In: Khanna R, ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications 1994; 10: Suzuki K, Twardowski ZJ, Nolph KD, Khanna R, Moore HL. Absorption of iron dextran from the peritoneal cavity ofrats. In: Khanna R, ed. Advances in
7 peritoneal dialysis. Toronto: Peritoneal Dialysis Publications 1995; 11: Moore HL. A chronic catheter model for PD exchanges in the ambulatory rat.perit Dial Int 1992; 12(Suppl1): S Domoto DT, Martin KJ. Failure of CAPD patients to respond to an oral iron absorption test. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin 1992; 8: Fleming LW, Stewart WK, Parratt D. Dextran anti bodies, complement conversion and circulating immune complexes after intravenous iron dextran therapy in dialysed patients. Nephrol Dial Transplant 1992; 7: Carthew P,EdwardsRE, SmithAG, DormanB, Francis JE. Rapid induction of hepatic fibrosis in the gerbil after the parenteral administration of iron dextran complex. Hepatology 1991; 13: Schwartz KA, Fisher J, Adams ET. Morphological investigations of the guinea pig model ofiron overload. Toxicol Pathol1993; 21:
Chapter 2 Peritoneal Equilibration Testing and Application
Chapter 2 Peritoneal Equilibration Testing and Application Francisco J. Cano Case Presentation FW, a recently diagnosed patient with CKD Stage 5, is a 6-year-old boy who has been recommended to initiate
More informationPresternal Catheter Design An Opportunity to Capitalize on Catheter Immobilization
Advances in Peritoneal Dialysis, Vol. 26, 2010 Dale G. Zimmerman Presternal Catheter Design An Opportunity to Capitalize on Catheter Immobilization Effective immobilization of the peritoneal catheter has
More informationThe peritoneal equilibration test (PET) was developed THE SHORT PET IN PEDIATRICS. Bradley A. Warady and Janelle Jennings
Peritoneal Dialysis International, Vol. 27, pp. 441 445 Printed in Canada. All rights reserved. 0896-8608/07 $3.00 +.00 Copyright 2007 International Society for Peritoneal Dialysis THE SHORT PET IN PEDIATRICS
More information3/21/2017. Solute Clearance and Adequacy Targets in Peritoneal Dialysis. Peritoneal Membrane. Peritoneal Membrane
3/21/2017 Solute Clearance and Adequacy Targets in Peritoneal Dialysis Steven Guest MD Director, Medical Consulting Services Baxter Healthcare Corporation Deerfield, IL, USA Peritoneal Membrane Image courtesy
More informationPERITONEAL EQUILIBRATION TEST. AR. Merrikhi. MD. Isfahan University of Medical Sciences
PERITONEAL EQUILIBRATION TEST AR. Merrikhi. MD. Isfahan University of Medical Sciences INTRODUCTION The peritoneal equilibration test (PET) is a semiquantitative assessment of peritoneal membrane transport
More informationRenal Self Learning Package INTRODUCTION TO PERITONEAL DIALYSIS
Renal Self Learning Package INTRODUCTION TO PERITONEAL DIALYSIS St George Hospital Renal Department, reviewed 2017 St George Hospital Renal Department RENAL SELF LEARNING PACKAGE INTRODUCTION TO PERITONEAL
More informationCosmoFer. Dose Selection and Calculation Guide for intravenous administration. Low molecular weight iron dextran. Revised TDI tables
CosmoFer Low molecular weight iron dextran Dose Selection and Calculation Guide for intravenous administration Revised TDI tables low Mw iron dextran Before prescribing CosmoFer please refer to full local
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Guidelines
6. Type of peritoneal dialysis Date written: February 2003 Final submission: May 2004 Guidelines No peritoneal dialysis has proven to be superior to the two cuff standard Tenckhoff in the prevention of
More informationSt George & Sutherland Hospitals PERITONEAL DIALYSIS UNIT RENAL DEPARTMENT Workplace Instruction (Renal_SGH_WPI_097)
PERITONEAL DIALYSIS (PD) PERITONEAL EQUILIBRATION TEST (PET) Cross references NSW Health PD2007_036 - Infection Control Policy SGH-TSH CLIN027 - Aseptic Technique - Competency and Education Requirements
More information6. Type of peritoneal dialysis catheter
Blackwell Science, LtdOxford, UKNEPNephrology1320-53582004 Asian Pacific Society of NephrologyOctober 20049S3S59S64MiscType of peritoneal dialysis The CARI Guidelines NEPHROLOGY 2004; 9, S59 S64 Date written:
More informationDrugs Used in Anemia
Drugs Used in Anemia Drugs of Anemia Anemia is defined as a below-normal plasma hemoglobin concentration resulting from: a decreased number of circulating red blood cells or an abnormally low total hemoglobin
More informationObjectives. Peritoneal Dialysis vs. Hemodialysis 02/27/2018. Peritoneal Dialysis Prescription and Adequacy Monitoring
Peritoneal Dialysis Prescription and Adequacy Monitoring Christine B. Sethna, MD, EdM Division Director, Pediatric Nephrology Cohen Children s Medical Center Associate Professor Hofstra Northwell School
More informationCurrent situation and future of renal anemia treatment. FRANCESCO LOCATELLI
Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (2000) 15 [Suppl 4]: 33 42 Nephrology Dialysis Transplantation European Best Practice Guidelines 9 13 Anaemia management Claude Jacobs, Walter H. Hörl, Iain C. Macdougall, Fernando
More informationLLL Session - Nutritional support in renal disease
ESPEN Congress Leipzig 2013 LLL Session - Nutritional support in renal disease Peritoneal dialysis D. Teta (CH) Nutrition Support in Patients undergoing Peritoneal Dialysis (PD) Congress ESPEN, Leipzig
More informationChanges in the Peritoneal Equilibration Test in Selected Chronic Peritoneal Dialysis Patients1
hanges in the Peritoneal Equilibration Test in Selected hronic Peritoneal Dialysis Patients1 Wai-Kei Lo, Alessandra Brendolan, Barbara F. Prowant, Harold L. Moore, Ramesh Khanna, Zbylut J. Twardowski,
More informationPERITONEOSCOPIC PLACEMENT OF THE TENCKHOFF CATHETER: FURTHER CLINICAL EXPERIENCE
PERITONEOSCOPIC PLACEMENT OF THE TENCKHOFF CATHETER: FURTHER CLINICAL EXPERIENCE Stephen R. Ash*,*** Alan E. Handt** Richard Bloch*** SUMMARY In the past two and one-half years, 80 Tenckhoff peritoneal
More informationNew Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients
23. Berliner DialyseSeminar 1.-4. Dezember 2010 New Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients George R. Aronoff, MD, MS, FACP Professor of Medicine and
More informationThe Physiology of Peritoneal Dialysis As Related To Drug Removal
The Physiology of Peritoneal Dialysis As Related To Drug Removal Thomas A. Golper, MD, FACP, FASN Vanderbilt University Medical Center Nashville, TN thomas.golper@vanderbilt.edu Clearance By Dialysis Clearance
More informationIntravenous Iron Requirement in Adult Hemodialysis Patients
Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct
More informationOnce-weekly darbepoetin alfa is as effective as three-times weekly epoetin
Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly
More informationYEAR III Pharm.D Dr. V. Chitra
YEAR III Pharm.D Dr. V. Chitra Anemia can be defined as a reduction in the hemoglobin,hematocrit or red cell number. In physiologic terms an anemia is any disorder in which the patient suffers from tissue
More informationII 12, 2017, 4:45-5:15 PM
Page 1 Choosing the Most Appropriate PD Catheter by Preoperative Mapping PD Nursing Fundamentals II Sunday, March 12, 2017, 4:45-5:15 PM by John H. Crabtree, MD Since patients come in all sizes and shapes
More informationPART ONE. Peritoneal Kinetics and Anatomy
PART ONE Peritoneal Kinetics and Anatomy Advances in Peritoneal Dialysis, Vol. 22, 2006 Paul A. Fein, Irfan Fazil, Muhammad A. Rafiq, Teresa Schloth, Betty Matza, Jyotiprakas Chattopadhyay, Morrell M.
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement?
ADVANCES Vol. 1 No.1 22 We are pleased to introduce our newest NPA publication, Advances in Anemia Management. This quarterly publication will address contemporary issues relating to the treatment of anemia
More informationPeritoneal dialysis. Overview. Preparing for dialysis. Links to sections in topic Other topics available on website
Peritoneal dialysis This infokid topic is for parents and carers about children s kidney conditions. Visit www.infokid.org.uk to find more topics about conditions, tests & diagnosis, treatments and supporting
More informationHematopoiesis, The hematopoietic machinery requires a constant supply iron, vitamin B 12, and folic acid.
Hematopoiesis, 200 billion new blood cells per day The hematopoietic machinery requires a constant supply iron, vitamin B 12, and folic acid. hematopoietic growth factors, proteins that regulate the proliferation
More information2016 Annual Dialysis Conference Michelle Hofmann RN, BSN, CNN Renal Clinical Educator - Home
Fluid Management 2016 Annual Dialysis Conference Michelle Hofmann RN, BSN, CNN Renal Clinical Educator - Home Objectives Define euvolemia Determine factors which contribute to fluid imbalance Discuss strategies
More informationSelect the dialysis treatment option that is best for you and your family.
PEP CONNECT PEP Talk Outline P a t i e n t E d u c a t i o n P r o g r a m Your Treatment Options Part 1 Peritoneal Dialysis Select the dialysis treatment option that is best for you and your family. This
More informationWhat is a PET? Although there are many types of pets, we will be discussing the Peritoneal Equilibration Test
1 2 3 What is a PET? Although there are many types of pets, we will be discussing the Peritoneal Equilibration Test 4 Background information about the PET 1983 Dr. Twardowski and colleagues began measuring
More informationEvaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases.
Evaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases. Arif Sami Malik FICMS. Abstract Background:Correction of anemia as a result of renal
More informationAdvances in Peritoneal Dialysis, Vol. 23, 2007
Advances in Peritoneal Dialysis, Vol. 23, 2007 Antonios H. Tzamaloukas, 1,2 Aideloje Onime, 1,2 Dominic S.C. Raj, 2 Glen H. Murata, 1 Dorothy J. VanderJagt, 3 Karen S. Servilla 1,2 Computation of the Dose
More informationEfficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD
Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below
More informationWhat Does Peritoneal Thickness in Peritoneal Dialysis Patients Tell Us?
Advances in Peritoneal Dialysis, Vol. 23, 2007 Soner Duman, 1 Suha Sureyya Ozbek, 2 Ebru Sevinc Gunay, 1 Devrim Bozkurt, 1 Gulay Asci, 1 Savas Sipahi, 1 Fatih Kirçelli, 1 Muhittin Ertilav, 1 Mehmet Özkahya,
More informationPeritoneal Dialysis Prescriptions: A Primer for Nurses
Peritoneal Dialysis Prescriptions: A Primer for Nurses A Primer ABCs of PD R x Betty Kelman RN-EC MEd CNeph (C) Toronto General Hospital University Health Network Toronto, Ontario, Canada A moment to remember
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Monitoring patients on peritoneal dialysis GUIDELINES
Date written: August 2004 Final submission: July 2005 Monitoring patients on peritoneal dialysis GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationTidal peritoneal dialysis: Comparison of different tidal regimens and automated peritoneal dialysis
Kidney International, Vol. 57 (2000), 2603 2607 Tidal peritoneal dialysis: Comparison of different tidal regimens and automated peritoneal dialysis PETER H. JUERGENSEN, A. LOLA MURPHY, KATHY A. PHERSON,
More informationOptimization of Epoetin Therapy with Intravenous Iron Therapy in Hemodialysis Patients
J Am Soc Nephrol 11: 530 538, 2000 Optimization of Epoetin Therapy with Intravenous Iron Therapy in Hemodialysis Patients ANATOLE BESARAB,* NEETA AMIN, MUHAMMAD AHSAN,* SUSAN E. VOGEL,* GARY ZAZUWA,* STANLEY
More informationStrategies for iron supplementation: Oral versus intravenous
Kidney International, Vol. 55, Suppl. 69 (1999), pp. S-61 S-66 IRON THERAPY IN RENAL FAILURE PATIENTS Strategies for iron supplementation: Oral versus intravenous IAIN C. MACDOUGALL Department of Renal
More informationONLINE HEMODIALYSIS TRAINING SESSION 1
ONLINE HEMODIALYSIS TRAINING SESSION 1 This document is a supplement to the Online Training. Do not reproduce. Copyright Dialysis4Career. All Rights Reserved. The Renal System - A highly sophisticated
More informationHemodialysis is a life-sustaining procedure for the treatment of
The Dialysis Prescription and Urea Modeling Biff F. Palmer Hemodialysis is a life-sustaining procedure for the treatment of patients with end-stage renal disease. In acute renal failure the procedure provides
More informationPharmaceutics I صيدالنيات 1. Unit 2 Route of Drug Administration
Pharmaceutics I صيدالنيات 1 Unit 2 Route of Drug Administration 1 Routs of Drug administration The possible routes of drug entry into the body may be divided into two classes: Parenteral Rout Enteral Rout
More informationMaintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F
Maintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationPeritoneal Catheter Exit-Site Morphology and Pathology Peritoneal Dialysis International, Vol. 16 (1996), Supplement /96 $
Peritoneal Catheter Exit-Site Morphology and Pathology Peritoneal Dialysis International, Vol. 16 (1996), Supplement 3 0896-8608/96 $3.00 +.00 Printed in Canada. All rights reserved. Copyright 1996 International
More informationOPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease
Nephrol Dial Transplant (2007) 22 [Suppl 3]: iii2 iii6 doi:10.1093/ndt/gfm014 OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease W. H. Ho rl 1, I. C. Macdougall 2, J.
More informationA randomized controlled study of iron supplementation in patients treated with erythropoietin
Kidney International, Vol. 5 (1996), pp. 1694 1699 A randomized controlled study of iron supplementation in patients treated with erythropoietin lain C. MACDOUGALL, BEATRIZ TUCKER, JOANNE THOMPSON, CHARLES
More informationInjection Techniques Principles and Practice. Introduction. Learning Objectives 5/18/2015. Richard E. Castillo, OD, DO
Injection Techniques Principles and Practice Richard E. Castillo, OD, DO Administering injections is considered a routine clinic activity Safety demands knowledge of: Anatomy & Physiology Pharmacology
More informationHome Dialysis. Peritoneal Dialysis. Home Hemodialysis
Home Dialysis The information provided is not intended to be a substitute for professional medical advice. A licensed healthcare professional should be consulted for diagnosis and treatment of any and
More information02/21/2017. Assessment of the Peritoneal Membrane: Practice Workshop. Objectives. Review of Physiology. Marina Villano, MSN, RN, CNN
Assessment of the Peritoneal Membrane: Practice Workshop Marina Villano, MSN, RN, CNN marina.villano@fmc-na.com Objectives Briefly review normal peritoneal physiology including the three pore model. Compare
More informationDetermination of Peritoneal Transport Characteristics With 24-Hour Dialysate Collections: Dialysis Adequacy and Transport Test1
Determination of Peritoneal Transport Characteristics With 24-Hour Dialysate Collections: Dialysis Adequacy and Transport Test1 Michael V. Rocco,2 Jean R. Jordan, and John M. Burkart MV. Rocco, J.M. Burkart,
More informationPeritoneal Dialysis Program King Campus 2757 King Street East Hamilton, Ontario ext
Peritoneal Dialysis Program King Campus 2757 King Street East Hamilton, Ontario 905-522-1155 ext. 38275 1 Table of Contents Page What is peritoneal dialysis? 1 How does this happen? 1 What are the types
More informationPERITONEAL DIALYSIS PRESCRIPTION MANAGEMENT QUICK REFERENCE GUIDE
PERITONEAL DIALYSIS PRESCRIPTION MANAGEMENT QUICK REFERENCE GUIDE This quick reference guide will help serve as a reference tool for clinicians setting a patient s Peritoneal Dialysis (PD) prescription.
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Peritoneal transport and ultrafiltration GUIDELINES
Date written: January 2004 Final submission: May 2004 Peritoneal transport and ultrafiltration GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationA Case of Encapsulating Peritoneal Sclerosis Suspected to Result from the Use of Icodextrin Peritoneal Solution
Advances in Peritoneal Dialysis, Vol. 25, 2009 Hideki Kawanishi, Sadanori Shintaku, Masayuki Shishida, Misaki Morrishi, Shinichiro Tsuchiya, Kiyohiko Dohi A Case of Encapsulating Peritoneal Sclerosis Suspected
More informationDrug Use in Dialysis
(Last Updated: 08/22/2018) Created by: Socco, Samantha Drug Use in Dialysis Drambarean, B. (2017). Drug Use in Dialysis. Lecture presented at PHAR 503 Lecture in UIC College of Pharmacy, Chicago. DIALYSIS
More informationFistula First? Vascular Symposium 4/28/18
Fistula First? Vascular Symposium 4/28/18 Disclosure I have no financial interest to disclose connected to any of the information presented in this discussion Objectives Scope of Problem Benefits of PD
More informationVincenzo La Milia 1, Giuseppe Pontoriero 1, Giovambattista Virga 2 and Francesco Locatelli 1
Nephrol Dial Transplant (2015) 30: 1741 1746 doi: 10.1093/ndt/gfv275 Advance Access publication 16 July 2015 Ionic conductivity of peritoneal dialysate: a new, easy and fast method of assessing peritoneal
More informationDisease Pathogenesis and Research Progression of Renal Anemia
2018 3rd International Conference on Life Sciences, Medicine, and Health (ICLSMH 2018) Disease Pathogenesis and Research Progression of Renal Anemia Yingying Liu, Qi Jiang* Department of Nephrology, China-Japan
More informationEverFlow Dolphin Protect Higher performance, better protection
EverFlow Dolphin Protect Higher performance, better protection Now available with Glid In bevel for an even smoother insertion EverFlow Dolphin Protect long-term hemodialysis catheter EverFlow Dolphin
More informationEarly Estimation of High Peritoneal Permeability Can Predict Poor Prognosis for Technique Survival in Patients on Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 22, 2006 Hidetomo Nakamoto, 1,2 Hirokazu Imai, 2 Hideki Kawanishi, 2 Masahiko Nakamoto, 2 Jun Minakuchi, 2 Shinichi Kumon, 2 Syuichi Watanabe, 2 Yoshhiko Shiohira,
More informationEnd-Stage Renal Disease. Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology
End-Stage Renal Disease Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology ESRD : Life with renal replacement therapy CASE: 18 month old male with HUS develops ESRD PD complicated
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals
ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationPeritoneal Dialysis Catheter Placement. Peritoneal Dialysis Catheter Placement. Peritoneal Dialysis Catheter Placement
ASDIN Advanced Techniques Pre-course Feb. 24, 2012 New Orleans, La Randall L. Rasmussen, MD Special thank you to Drs. Rajeev Narayan, San Antonio, Tx and Hemant Dhingra, Fresno Ca for lending me slides
More informationPeritoneal Dialysis International, Vol.18, pp /98 $ TRANSPORT KINETICS IN CHILDREN
Peritoneal Dialysis International, Vol.18, pp 590-597 0896-8608/98 $300 + 00 Printed in Canada All rights reserved Copyright 1998 International Society for Peritoneal Dialysis INFLUENCE OF AGE, TIME, AND
More informationInfluence of Water Diuresis on Antimicrobial
Influence of Water Diuresis on Antimicrobial Treatment of Enterococcal Pyelonephritis SANDRA P. LEVISON and DONALD KAYE From the Department of Medicine, The Medical College of Pennsylvania, Philadelphia,
More informationΑκτινοθεραπευτική Ογκολογία & Παθολογική Ογκολογία
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A problem focused history; A problem focused examination; Straightforward medical
More informationVancomycin: Class: Antibiotic.
Vancomycin: Class: Antibiotic. Indications: Treatment of patients with infections caused by staphylococcal species and streptococcal Species. Available dosage form in the hospital: 1G VIAL, 500MG VIAL.
More informationHemodialysis patients with endstage
Insights into Achieving Target Hemoglobin Levels: Increasing the Serum Ferritin Parameter Scott Bralow, DO Dr. Scott Bralow is the Medical Director of the Renal Center of Philadelphia. Evidence suggests
More informationImad Ahmed MD. Renal Associates of West Michigan
Imad Ahmed MD Renal Associates of West Michigan ESRD Facts: - Medicare funded program - Cost - Significant mortality and morbidity - Reduced quality of life - Shrinking donor pool ESRD CAUSES - DM - Hypertension
More informationAdequacy of automated peritoneal dialysis with and without manual daytime exchange: A randomized controlled trial
http://www.kidney-international.org & 2006 International Society of Nephrology original article Adequacy of automated peritoneal dialysis with and without manual daytime exchange: A randomized controlled
More informationUW MEDICINE PATIENT EDUCATION. Peritoneal Dialysis. A treatment option for kidney disease. There are 2 types of PD: continuous ambulatory
UW MEDICINE PATIENT EDUCATION Peritoneal Dialysis A treatment option for kidney disease Class Goals 1. Understand the purpose and basic principles of continuous ambulatory peritoneal dialysis (CAPD). 2.
More informationBacterial peritonitis is a common complication of peritoneal
Peritoneal Dialysis International, Vol. 27, pp. 79 85 Printed in Canada. All rights reserved. 0896-8608/07 $3.00 +.00 Copyright 2007 International Society for Peritoneal Dialysis VANCOMYCIN DISPOSITION
More informationUltrafiltration and solute kinetics using low sodium peritoneal dialysate
Kidney International, Vol. 48 (1995), pp. 1959 1966 Ultrafiltration and solute kinetics using low sodium peritoneal dialysate JOHN K. LEYPOLDT, DAVID I. CHARNEY, ALFRED K. CHEUNG, CYNTHIA L. NAPRESTEK,
More informationA rationale for an individualized haemoglobin target
Nephrol Dial Transplant (2002) 17 [Suppl 6 ]: 2 7 A rationale for an individualized haemoglobin target Norman Muirhead University of Western Ontario, London, Ontario, Canada Abstract Despite the use of
More informationImaging of Peritoneal Catheter Tunnel Infection Using Positron-Emission Tomography
Advances in Peritoneal Dialysis, Vol. 26, 2010 Pooja Singh, 1,2 Brenda Wiggins, 1 Yijuan Sun, 1,2 Karen S. Servilla, 1,2 Reuben E. Last, 3,4 Michael F. Hartshorne, 5,6 Antonios H. Tzamaloukas 1,2 Imaging
More informationTroubleshooting the Dysfunctional PD Catheter
Troubleshooting the Dysfunctional PD Catheter ASDIN Annual Scientific Meeting Phoenix, Arizona February, 2014 Corporate Relationships in PD Area-Dr. Ash Developed Y-Tec System for placing PD catheters
More informationAccidental Insertion of a Peritoneal Dialysis Catheter in the Urinary Bladder
Published online: April 26, 2018 2018 The Author(s) Published by S. Karger AG, Basel This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/services/openaccesslicense).
More informationSichol sooksee,rn. Hemodialysis Unit Rajavej Chiang Mai Hospital
Sichol sooksee,rn. Hemodialysis Unit Rajavej Chiang Mai Hospital Button hole or Ladder?? Vascular Access Cannulation It s a Life Line of Hemodialysis patient Arterio-venous fistula(avf) is the K/DOQI
More informationHyperphosphatemia is a strong predictor of overall
Peritoneal Phosphate Clearance is Influenced by Peritoneal Dialysis Modality, Independent of Peritoneal Transport Characteristics Sunil V. Badve,* Deborah L. Zimmerman,* Greg A. Knoll, * Kevin D. Burns,*
More informationPeritoneal Dialysis International, Vol. 16, pp /96$300+00
Peritoneal Dialysis International, Vol. 16, pp 302-306 0896-8608/96$300+00 Printed in Canada All rights reserved Copyright 1996 International Society for Peritoneal Dialysis CONTINUOUS PERITONEAL DIAL
More informationHematocrit Levels and Hospitalization Risks in Hemodialysis Patients
J Am Soc Nephrol 10: 1309 1316, 1999 Hematocrit Levels and Hospitalization Risks in Hemodialysis Patients HONG XIA,* JIM EBBEN,* JENNIE Z. MA, and ALLAN J. COLLINS *Nephrology Analytical Services, Minneapolis
More informationComparison of temporary and permanent catheters for acute peritoneal dialysis
Archives of Disease in Childhood, 1988, 63, 827-831 Comparison of temporary and permanent for acute peritoneal dialysis S N WONG AND D F GEARY Division of Nephrology, Department of Paediatrics, Hospital
More informationIntravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University
Intravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University Use of IV Iron There are increasing data regarding safety of IV iron. IV iron is superior to
More informationIV therapy. By: Susan Mberenga, RN, MSN. Copyright 2016, 2013, 2010, 2006, 2002 by Saunders, an imprint of Elsevier Inc.
IV therapy By: Susan Mberenga, RN, MSN 1 IV Therapy Types of solutions Isotonic Hypotonic Hypertonic Caution: Too rapid or excessive infusion of any IV fluid has the potential to cause serious problems
More informationPharmacokinetics I. Dr. M.Mothilal Assistant professor
Pharmacokinetics I Dr. M.Mothilal Assistant professor DRUG TRANSPORT For a drug to produce a therapeutic effect, it must reach to its target and it must accumulate at that site to reach to the minimum
More informationFOUR. Clinical Indicators of Care
Clinical Indicators of Care T FOUR The great questions of the time are not decided by speeches and majority decisions but by iron and blood. Otto von Bismarck, Speech to the Prussian Diet 78 ž 2000 ATLAS
More informationDianeal Peritoneal Dialysis Solutions
Dianeal Peritoneal Dialysis Solutions Name of the medicine Dianeal PD-2, PD-4 and 1 mmol/l Calcium Peritoneal Dialysis Solutions. Description Dianeal PD-2, PD-4 and 1 mmol/l Calcium Peritoneal Dialysis
More informationAus Artificial Uretheral Sphincter Port System
NORFOLK VET PRODUCTS the AUS for the long-term relief of incontinence in dogs and cats making life easier for pets Speciality Medical Devices For The Veterinary Community the Aus Artificial Uretheral Sphincter
More informationPeritoneal dialysis (PD) patients have increased
Peritoneal Dialysis International, Vol. 23, pp. 249 254 Printed in Canada. All rights reserved. 0896-8608/03 $3.00 +.00 Copyright 2003 International Society for Peritoneal Dialysis RISK FACTORS FOR ABDOMINAL
More informationChapter 7: Adequacy of Haemodialysis and Serum Bicarbonate
Chapter 7: Adequacy of Haemodialysis and Serum Bicarbonate Summary. The urea reduction ratio (URR) has been rising year on year but now appears to have reached a plateau.. The URR increases the longer
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPeritoneal dosing recommendation gabapentin
Peritoneal dosing recommendation gabapentin Search Latest news from AFSPA on Federal Employees Health. 8-4-2010 Information for Health Care Professionals : Cannabis (marihuana, marijuana) and the cannabinoids
More informationToxicity of intraperitoneal bisulfite
Toxicity of intraperitoneal bisulfite Studies were carried out in animals to investigate the toxicity of intraperitoneal bisulfite. The LDso (dose lethal to 50 per cent of the animals) for a single intraperitoneal
More informationIron Status in Chronic Renal Failure with Anemia
Chattagram Maa-O-Shishu Hospital Medical College Journal DOI: 10.11566/cmosh.2013.1201.12 Original Article Iron Status in Chronic Renal Failure with Anemia Shaheda Khanam 1 * Noorzahan Begum 2 AMM Ehteshamul
More information03/20/2019. Thank you for the invitation to speak. I have no conflicts of interest
Raj Munshi, MD Annual Dialysis Conference 2019 Thank you for the invitation to speak I have no conflicts of interest Expected remaining lifetime in years of prevalent patients by initial ESRD modality,
More informationClaudio Ronco, MD Dipartimento di Nefrologia, Dialisi & Trapianto Renale International Renal Research Institute Ospedale San Bortolo - Vicenza
Claudio Ronco, MD Dipartimento di Nefrologia, Dialisi & Trapianto Renale International Renal Research Institute Ospedale San Bortolo - Vicenza Four Areas where telemedicine can be useful in Nephrology
More informationLife Science Journal 2013;10(4)
Short Term Low Dose Intravenous Ascorbic Acid in Functional Iron Deficiency Anemia in Hemodialysis Patients Magdy El-Sharkawy¹, Walid Bichari ¹, Mostafa Kamel ¹ and Hanaa Fathey ² ¹ Internal Medicine and
More informationInnovation in Technology II: Changed and Improved Design. PD Catheters- designs. Bharat Sachdeva MD LSU Shreveport
Innovation in Technology II: Changed and Improved Design PD Catheters- designs Bharat Sachdeva MD LSU Shreveport What s at risk? Why Is Material/Design Important? Reduce risk for transfer to HD Displacement
More information